Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06141187

Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy.

The purpose of this randomized double-blind clinical trial is to determine the efficacy of percutaneous vertebroplasty (PVP) in relieving severe pain in patients with MRI-verified acute or sub-acute osteoporotic vertebral compression fractures (OVCFs) compared to sham as well as examine the socio-economic implications associated with performing vertebroplasty.

The primary outcome is improvement of pain intensity as measured on a Visual Analog Scale (VAS, 0 to100) 12 weeks after treatment. Secondary outcomes include patient-reported back-related disability, patient-reported quality of life, spinal sagittal balance, complications associated with the procedure, incidence of new OVCFs and socioeconomic costs.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rygcenter Syddanmark

Middelfart, Fyn, 5500, Denmark

Location status: Recruiting

Location contact

Andreas K Andresen, MD

CONTACT

[email protected]

Mikkel Ø Andersen, MD

CONTACT

[email protected]

About this study

The study design is a prospective, double-blind, randomized, sham-controlled clinical trial where patients are stratified into either involvement of 1-2 vertebral levels or 3-4 levels and randomized to either vertebroplasty or a sham operation. The trial is designed in accordance with the SPIRIT guidelines.

Patients will be examined in the outpatient clinic at the Center for Spine Surgery and Research, Lillebaelt Hospital, Kolding, Denmark. MRI scans and X-ray images will be performed at the radiology department at the hospital. Experienced neuro-radiologists carry out image analyses.

Spine surgeons who are experienced in PVP will perform the surgical procedures. Anaesthesiologists and spine surgeons are present at the facility in case of complications, following recommendations by the National Health Authority and have the capacity/capability to decompress the spinal canal in case of cement leakage.

Study subjects will be recruited from patients diagnosed with painful x-ray verified vertebral compression fractures in the Region of southern Denmark. The patients will be identified and referred to the trial site by the patients' general practitioner, chiropractor, physiotherapist, or from hospital inpatient and emergency departments in the region of Southern Denmark.

Subjects will initially be stratified into two groups based on the number of OVCFs into 1-2 levels or 3-4 levels. Within each of these two groups, randomization sheets in varying blocks of 8 with an equal number of PVP and sham patients in each block will be generated using software (www.randomizer.org) and will be placed in numbered, opaque, sealed envelopes. Treatment group assignment will be performed by a scrub nurse in the surgical theatre after the patient is draped but prior to skin incision. Throughout the trial, only the surgeon and the OR-nurse will have knowledge of the treatment assignment. The patient and all assessors remain blinded to the treatment group throughout the study.

During hospitalization, perioperative data on operation time, theater time and complications will be collected from the operating room staff during surgery. Upon discharge, length of stay will be recorded for each patient. After discharge, all visits to the outpatient clinic, either to the surgeon, nurse or physiotherapist as well as phone calls with questions regarding their procedure to the surgical nurse and time spent will be recorded.

Patients will be seen in the clinic for evaluation at 4, 12, and 52 weeks after treatment. MRI and full-standing anteroposterior and lateral radiographs will be taken at the 12-week follow-up time point. This will allow for identification of any healing at the index level as well as any new-onset OVCFs.

Treatment effectiveness analyses of the randomized trial data will performed on an intent-to-treat basis. Enrolled patients and outcome assessors will remain blinded for the duration of the trial. The 12-week follow-up will be the primary endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 50+ and diagnosed with symptomatic osteoporotic spinal compression fractures between T6 and L5 (incl).
  • Focal tenderness on the level of the vertebral fracture.
  • Fractures verified with oedema of the relevant vertebra on the MRI STIR sequence
  • Osteoporotic Fractures type 1-4.
  • Fracture involves no more than 4 vertebral body levels.
  • PVP can be done in one session.
  • Back pain score measured on a Visual Analog Scale (VAS, 0 to 100) ≥ 60.
  • Able to understand and read Danish.
  • Written informed consent.
  • Relevant pain started ≤ 3 months prior to enrollment.

Exclusion criteria

  • - Contra-indications for spine surgery.
  • Platelets < 30 mia/l.
  • Osteoporotic Fractures type 5 and Pincer-type.
  • Complete collapse of the vertebral body precluding insertion of needle.
  • Presence of neurologic deficit.
  • Contraindications for MRI scanning.
  • Psychological or psychiatric disorder that is expected to interfere with compliance.
  • Active malignancy.
  • Mini Mental State Examination (MMSE) test score below 24.
  • History of chronic back pain requiring ongoing opiate use.
  • Systemic or local infection of the spine.

Treatment and study plan

vertebroplasty

Procedure

PVP

Sham vertebroplasty

Procedure

Sham PVP

Primary outcomes

  1. Pain intensity using the 100-point VAS

    Time frame: VAS will be recorded at time of randomization and after 1, 2, 3, 4 and 5 days, and after 2, 4, 8 and 12 weeks, and finally at 12 months and 24 months post-randomization

    Self-reported average pain intensity over the previous 24 hours, using the 100-point VAS will be recorded at time of randomization and after 1, 2, 3, 4 and 5 days, and after 2, 4, 8 and 12 weeks, and finally at 12 months and 24 months post-randomization

Secondary outcomes

  1. Patient-reported disability.

    Time frame: Recorded at enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization

    The patients rate their disability at the time of enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization using the Oswestry Disability Index (ODI) questionnaire

  2. Health-related quality of life.

    Time frame: Recorded at enrolment and at 4 and 12 weeks, 12 and 24 months post-randomization

    HRQL on the EuroQol 5-dimension 5-level (EQ-5D-5L)

  3. Global Perceived Effect scale

    Time frame: Recorded at 4 and 12 weeks, 12 and 24 months post-randomization

    Global perceived effect of the treatment will be assessed using single question with seven-point descriptive scaling with the answers

  4. Sagittal balance

    Time frame: Recorded at enrolment and 12 months post-randomization

    Full-length 36" lateral scoliosis radiographs taken with hands placed on the clavicles will be obtained to measure Pelvic Incidence, Pelvic Tilt, Sacral Slope, C7-Plumb Line and Lumbar Lordosis/Thoracic Kyphosis both preoperatively and after 12 months

  5. Societal costs of treatment

    Time frame: Recorded 1 day at discharge and 12 months post-randomization

    The intervention costs will be obtained using data from hospital registries about outpatient contacts, inpatient admissions and length of stay, staff time for surgical procedure, recovery and rehabilitation.

Study contacts

Contact information is provided by the study sponsor or research team.

Mikkel Ø Andersen, MD

CONTACT

[email protected]

+45 2320 9173

Sponsors and collaborators

Lead sponsor

Spine Centre of Southern Denmark

Other

Registry information

Official study title

Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy: a Single-center, Double-blind Randomized Controlled Clinical Trial

Acronym: VOPE2

Important dates

Study start
2024
Primary completion
2028
Study completion
2030
First posted
Nov 21, 2023
Registry last updated
Jan 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.